Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden Anstalt des öffentlichen Rechts des Freistaates Sachsen
ZKN Logo
  • The Center
    • Multiple Sclerosis Center Dresden
      • Patient Information
      • Contact MSC
      • Physicians & Nurses
      • Study Team
      • Neuropsychology
    • Mobility Center
      • The Mobility Center
      • Walking Assessment
      • Jump Assessment
      • DIERS
      • EMIQ
      • Projects
    • Neuroimmunological Laboratory
      • The NIL
      • Neurofilament light chain
    • Autonomic & Neuroendocrinological Functional Laboratory
      • The ANF
      • ANF Assessment
    • MS Living Lab
    • Management & Science
      • Team Management & Science
      • Projects
      • eHealth & Analytics
        • MSDS 3D
        • MSDS Clinic & Practice
        • MS-HRS
        • MTRS
      • Multiple Sclerosis Management
  • Aktuelles
    • Neuigkeiten
    • Publikationen
    • Veranstaltungen
      • Adventssymposium
      • Multiple Sklerose 360°
      • Welt-MS-Tag 2021
    • Doktorarbeiten
    • Jobs
    • Kontakt
  • Podcasts & Newsletter
    • Newsletter
    • Patienten-Podcast
    • Ärzte-Podcast
  • Studien
    • Interventionelle Studien
    • B-SHUTTLE
    • Nicht-interventionelle Studien
    • MS PATHS
    • Konectom
    • Sprachanalyse
English (UK)
Deutsch
English (UK)

Treatment of multiple sclerosis with glatiramer acetate - New information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies

MS Treatments

Jahr

Publikationsjahr
2002

Autoren

Autorenliste der Publikation
Ziemssen T, Neuhaus O, Farina C, Hartung HP, Hohlfeld R.

Verlag

Publisher-Information
Nervenarzt 2002;73(4):321-331.

Link

Zur Publikation (externer Server)
https://link.springer.com/article/10.1007/s00115-001-1257-0

Tags

Forschungsthemen
Multiple SkleroseMS Behandlung
MSZTreatments2002

  • COVID-19 and multiple sclerosis: challenges and lessons for patient care

    Multiple Sclerosis
    Jahr
    2024

  • A future of AI-driven personalized care for people with multiple sclerosis

    MASC
    Jahr
    2024

  • Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374

    NIL
    Jahr
    2024

  • Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

    MS Treatments
    Jahr
    2024

  • Evaluation of therapy satisfaction with cladribine tablets in patients with RMS: Final results of the non-interventional study CLEVER

    MS Treatments
    Jahr
    2024
  • Start
  • Aktuelles
  • Publikationen
  • MS Treatments
  • Treatment of multiple sclerosis with glatiramer acetate - New information about its mechanisms of action, pharmacokinetics, adverse effects and clinical studies
Impressum & Datenschutz

© 2024
Universitätsklinikum C.G. Carus Dresden an der Technischen Universität Dresden